Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes

Blood (2023) 142 (Supplement 1): 866.

https://doi.org/10.1182/blood-2023-182100

Published: 2023

Journal Articles

The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia

Elena Kuzmina, Ekaterina Chelysheva, Elza Lomaia, Elena V Morozova, Oleg Shukhov, Anna Petrova, Tamara Chitanava, Julia Vlasova, Evgenia Sbitiakova, Natalia Lazorko, Irina Nemchenko, Anastasiya Vitalievna Bykova, Margarita Gurianova, Alina Kokhno, Anna Turkina

Blood (2023) 142 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2023-181789

Published: 2023

Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Blood (2023) 142 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2023-187744

Published: 2023

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Blood (2022) 140 (Supplement 1): 1498–1500.

https://doi.org/10.1182/blood-2022-159993

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia

Anna Turkina, Elena A. Kuzmina, Elza Lomaia, Elena Morozova, Oleg A. Shukhov, Anna N. Petrova, Tamara Chitanava, Julia J. Vlasova, Ekaterina Yu. Chelysheva, Evgeniya Sbityakova, Irina S. Nemchenko, Anastasiya V. Bykova, Margarita A. Gurianova, Alina V. Kokhno, Elena N. Parovichnikova

Blood (2022) 140 (Supplement 1): 9654–9655.

https://doi.org/10.1182/blood-2022-162268

Published: 2022

Journal Articles

ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors

Massimo Breccia, Anna Turkina, Carla Boquimpani, Charles Chuah, Giora Sharf, Luigi Di Caprio, Matthias Hoch, Justin Yssel, Yifan Zhang, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 9635–9636.

https://doi.org/10.1182/blood-2022-157991

Published: 2022

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood (2021) 138 (21): 2031–2041.

https://doi.org/10.1182/blood.2020009984

Published: 2021

Includes: Supplemental data

Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Blood (2021) 138 (21): 2042–2050.

https://doi.org/10.1182/blood.2021012082

Published: 2021

Includes: Supplemental data

Journal Articles

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Blood (2015) 126 (23): 5150.

https://doi.org/10.1182/blood.V126.23.5150.5150

Published: 2015

Journal Articles

Russian Registry of Chronic Myeloid Leukemia Management in Routine Clinical Practice-Local Therapy and Monitoring

Anna Turkina, Prof., MD, Anatoly Golenkov, MD, Lyudmila Napso, Irina Krylova, Tatiana Klitochenko, Olga Senderova

Blood (2015) 126 (23): 5156.

https://doi.org/10.1182/blood.V126.23.5156.5156

Published: 2015

Journal Articles

Introduction of a Treatment Approach for Chronic Myeloid Leukemia and Pregnancy Considering Leukemic Burden and Pregnancy Terms

Ekaterina Chelysheva, Anna Turkina, Prof., MD, Evgenia Polushkina, Roman G. Shmakov, MD

Blood (2015) 126 (23): 5144.

https://doi.org/10.1182/blood.V126.23.5144.5144

Published: 2015

Journal Articles

Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia

Tamara Sorokina, MD, Irina Shipounova, PhD, Alexey Bigildeev, PhD, Nataliya Petinati, PhD, Nina I. Drize, PhD, Anna Turkina, Prof., MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD, Larisa A. Kuzmina, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G Savchenko, PhD MD

Blood (2015) 126 (23): 4768.

https://doi.org/10.1182/blood.V126.23.4768.4768

Published: 2015

Journal Articles

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Vasily Shuvaev, MD, Kudrat Abdulkadyrov, MD PhD, Anna Turkina, Prof., MD, Irina Martynkevich, MD PhD, Ekaterina Chelysheva, MD PhD, Mikhail Fominykh, MD, Valentin Martchenko

Blood (2015) 126 (23): 3293.

https://doi.org/10.1182/blood.V126.23.3293.3293

Published: 2015

Journal Articles

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Blood (2015) 126 (23): 2780.

https://doi.org/10.1182/blood.V126.23.2780.2780

Published: 2015

Journal Articles

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Markus Pfirrmann, Joerg Hasford, MD, Susanne Saussele, Anna Turkina, Prof., MD, Witold Prejzner, MD, Juan Luis Steegmann, MD, Bengt Simonsson, MD, Andrey Zaritskey, MD, Adriana Colita, MD, Daniela Zackova, MD, Jeroen Janssen, MD, Francisco Cervantes, Karel Indrak, MD, Joelle Guilhot, PhD, Ruediger Hehlmann, MD, Michele Baccarani, MD

Blood (2015) 126 (23): 595.

https://doi.org/10.1182/blood.V126.23.595.595

Published: 2015

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

NARROW

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia

ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Russian Registry of Chronic Myeloid Leukemia Management in Routine Clinical Practice-Local Therapy and Monitoring

Introduction of a Treatment Approach for Chronic Myeloid Leukemia and Pregnancy Considering Leukemic Burden and Pregnancy Terms

Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only